Close Menu
Truth Republican
  • Home
  • News
  • Politics
  • Business
  • Guns & Gear
  • Healthy Tips
  • Prepping & Survival
  • Videos
Facebook X (Twitter) Instagram
Truth Republican
  • Home
  • News
  • Politics
  • Business
  • Guns & Gear
  • Healthy Tips
  • Prepping & Survival
  • Videos
Newsletter
Truth Republican
You are at:Home»Healthy Tips»Popular weight-loss drugs show promising new power against debilitating migraines
Healthy Tips

Popular weight-loss drugs show promising new power against debilitating migraines

Buddy DoyleBy Buddy DoyleJuly 2, 2025No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp
Popular weight-loss drugs show promising new power against debilitating migraines
Share
Facebook Twitter LinkedIn Pinterest Email

NEWYou can now listen to Fox News articles!

Beyond diabetes control and weight management, GLP-1s could have yet another benefit: helping with migraines.

In a small study, a GLP-1 drug shrank the number of days people spent with a migraine by almost half in a given month.

Presented at the European Academy of Neurology Congress in Helinski, Finland, on June 21, the results suggest promising future uses of the popular obesity and diabetes drugs.

WHO SHOULD BE TAKING WEIGHT-LOSS DRUGS? DOCTORS SHARE BEST CANDIDATES

Nearly 40 million Americans deal with migraines, according to the World Health Organization (WHO) — and for many, they’re more than just a headache.

Migraines are the second-leading cause of disability worldwide, the above agency states, with symptoms including severe headaches, nausea and sensitivity to light often disrupting daily activities. 

Previous studies have shown that GLP-1s can reduce pressure inside the skull, which is a possible cause of migraines, according to multiple health organizations.

Neurologist and study lead Simone Braca of the University of Naples Federico II in Italy, along with his colleagues, explored whether liraglutide, an earlier version of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), could help migraine sufferers. 

“Most patients felt better within the first two weeks and reported quality of life improved significantly.”

Thirty-one adults, 26 of them women, got daily injections of liraglutide for 12 weeks. The participants, who all met the criteria for obesity, also continued to take their current migraine medications.

At the start of the experiment, participants reported headaches about 20 days out of a month. After 12 weeks of liraglutide, the average number dropped to about 11 days.

“Most patients felt better within the first two weeks and reported quality of life improved significantly,” said Braca in a press release for the study, which was published in the journal Headache last month.

A woman prepares to administer an insulin injection

The relief from migraines lasted for the full three-month observation period, the researcher noted, although weight loss was “modest and statistically non-significant.”

Participants’ weight stayed about the same during the trial, suggesting that the headache reductions weren’t tied to weight loss.

WEIGHT-LOSS MEDICATIONS MAY ALSO BENEFIT COMMON MEDICAL PROBLEM, STUDY FINDS

“Liraglutide is a ‘middle-aged’ GLP-1, with Ozempic and Mounjaro being newer,” Dr. Sue Decotiis, a triple board-certified weight loss specialist in New York City, told Fox News Digital.

Decotiis, who was not involved in the study, said that liraglutide is not as effective as its newer cousins for weight loss or diabetes, and is not frequently used for these purposes.

Woman holding her head during a migraine

“Many pharmacies are not even stocking it due to declining demand, yet it gets into the brain well enough to reduce migraines,” she noted.

Potential limitations

The trial didn’t include a comparison group, and participants and researchers all knew that everyone received liraglutide, the researchers noted. 

Mild gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants, but did not lead to treatment discontinuation.

Further research may include other groups, such as control groups and people without obesity, to compare the drug’s effects.

“The study was very small,” Decotiis confirmed to Fox News Digital.

Man holding head while he experiences a migraine

Given its size and brief duration, the findings could be limited until further research is conducted, according to the expert.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The researchers also tested only one drug, liraglutide, “which is not used as frequently in the general population as semaglutide or tirzepatide are,” Decotiis added.

For more Health articles, visit www.foxnews.com/health

Next, the team is planning a randomized, double-blind trial that will also measure pressure inside the skull. 

“We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects,” Braca said in the same press release.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleFormer FBI Director Comey’s daughter suffers high-profile loss as prosecutor in Diddy trial
Next Article Trump’s tariff policies reshape online shopping habits, new report finds

Related Articles

Weight-loss drugs now linked to cancer protection in women, major new study reveals

Weight-loss drugs now linked to cancer protection in women, major new study reveals

September 29, 2025
7 common fitness mistakes older adults make and how to avoid them for better workouts

7 common fitness mistakes older adults make and how to avoid them for better workouts

September 27, 2025
Common vitamin shown to slash skin cancer risk in some groups, study suggests

Common vitamin shown to slash skin cancer risk in some groups, study suggests

September 26, 2025
Autism symptoms in adults and new virus surge, plus GLP-1 benefits

Autism symptoms in adults and new virus surge, plus GLP-1 benefits

September 26, 2025
Best time to get the flu vaccine this fall as influenza season approaches

Best time to get the flu vaccine this fall as influenza season approaches

September 26, 2025
Blinded Army veteran who survived attack turns trauma into mission to help others

Blinded Army veteran who survived attack turns trauma into mission to help others

September 26, 2025
No more injections? New pill could replace Ozempic and Wegovy for weight loss

No more injections? New pill could replace Ozempic and Wegovy for weight loss

September 25, 2025
Weight-loss doctor shares how GLP-1s could rewire body against disease

Weight-loss doctor shares how GLP-1s could rewire body against disease

September 25, 2025
Dangerous spike in superbug infections surges across US as experts share cautions

Dangerous spike in superbug infections surges across US as experts share cautions

September 24, 2025
Don't Miss
Most Durable Rugged Smartphone – Doogee S97 Pro Review

Most Durable Rugged Smartphone – Doogee S97 Pro Review

Israel Continues War On Gaza As Trump Says “Something Special” Is Coming

Israel Continues War On Gaza As Trump Says “Something Special” Is Coming

CQB Firepower: SAINT Victor 5.5″ 9mm

CQB Firepower: SAINT Victor 5.5″ 9mm

Electronic Arts going private major B buyout deal from investor group

Electronic Arts going private major $55B buyout deal from investor group

Latest News
Bears coach Ben Johnson’s awkward exchange with NFL reporter sparks social media frenzy

Bears coach Ben Johnson’s awkward exchange with NFL reporter sparks social media frenzy

September 29, 2025
TOP 10 BEST WATER FILTERS FOR BACKPACKING & SURVIVAL

TOP 10 BEST WATER FILTERS FOR BACKPACKING & SURVIVAL

September 29, 2025
Prediction market traders give Mamdani 84% chance of winning New York mayoral race

Prediction market traders give Mamdani 84% chance of winning New York mayoral race

September 29, 2025
Supreme Court showdown: Trump’s strategy to test limits of his power could spell doom for administrative state

Supreme Court showdown: Trump’s strategy to test limits of his power could spell doom for administrative state

September 29, 2025
Reporter’s Notebook: Trump holds bipartisan meeting with congressional leaders as Wednesday shutdown looms

Reporter’s Notebook: Trump holds bipartisan meeting with congressional leaders as Wednesday shutdown looms

September 29, 2025
Copyright © 2025. Truth Republican. All rights reserved.
  • Privacy Policy
  • Terms of use
  • Contact

Type above and press Enter to search. Press Esc to cancel.